Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 14;19(46):8703-8.
doi: 10.3748/wjg.v19.i46.8703.

Long-term follow up of endoscopic resection for type 3 gastric NET

Affiliations

Long-term follow up of endoscopic resection for type 3 gastric NET

Yong Hwan Kwon et al. World J Gastroenterol. .

Abstract

Aim: To clarify the short and long-term results and to prove the usefulness of endoscopic resection in type 3 gastric neuroendocrine tumors (NETs).

Methods: Of the 119 type 3 gastric NETs diagnosed from January 1996 to September 2011, 50 patients treated with endoscopic resection were enrolled in this study. For endoscopic resection, endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) was used. Therapeutic efficacy, complications, and follow-up results were evaluated retrospectively.

Results: EMR was performed in 41 cases and ESD in 9 cases. Pathologically complete resection was performed in 40 cases (80.0%) and incomplete resection specimens were observed in 10 cases (7 vs 3 patients in the EMR vs ESD group, P = 0.249). Upon analysis of the incomplete resection group, lateral or vertical margin invasion was found in six cases (14.6%) in the EMR group and in one case in the ESD group (11.1%). Lymphovascular invasions were observed in two cases (22.2%) in the ESD group and in one case (2.4%) in the EMR group (P = 0.080). During the follow-up period (43.73; 13-60 mo), there was no evidence of tumor recurrence in either the pathologically complete resection group or the incomplete resection group. No recurrence was reported during follow-up. In addition, no mortality was reported in either the complete resection group or the incomplete resection group for the duration of the follow-up period.

Conclusion: Less than 2 cm sized confined submucosal layer type 3 gastric NET with no evidence of lymphovascular invasion, endoscopic treatment could be considered at initial treatment.

Keywords: Carcinoid; Endoscopic resection; Neuroendocrine tumor; Stomach; Treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of type 3 gastric neuroendocrine tumors. Of all type 3 gastric neuroendocrine tumors (NETs) (n = 119), 39 patients were treated with surgery, 50 patients were treated using an endoscopic method, and 15 patients were followed up only by observation. In the endoscopic treatment group, 41 patients were treated with endoscopic mucosal resection (EMR), and nine patients were treated with endoscopic submucosal dissection (ESD). Upon analysis of the resected specimens, histologically incomplete resections were found in seven cases in the EMR group and three cases in the ESD group, and lymphovascular invasion was found in one case in the EMR group and two cases in the ESD group. All cases of lymphovascular invasion were treated with an additional operation. During the median follow-up duration (46 mo), there was no recurrence of gastric NETs in the endoscopic resection group.

Similar articles

Cited by

References

    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. - PubMed
    1. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32. - PubMed
    1. Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42:664–671. - PubMed
    1. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563–2569. - PubMed
    1. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84:158–164. - PubMed

MeSH terms